Exchange: NASDAQ·Updated 04:03 AM EDT

SCTX Scribe Therapeutics

$28.49
$0.42
(1.50%)
Pre-Market
Prev Close $28.07
Reported EarningsSep 2
Mkt Cap$531.03M
Vol31.00

About SCTX

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.
46

Neutral Sentiment

How do you feel about SCTX?

Advertisement|Remove ads.